Long-term partial response after camrelizumab plus chemotherapy induction therapy and camrelizumab maintenance therapy beyond two years in squamous non-small cell lung cancer: a case report
For squamous NSCLC patients without a CR to induction therapy, continuing ICI maintenance therapy beyond 2 years-rather than discontinuing treatment-may potentially extend overall survival.
Authors
- Xiaoning Lu (ORCID: https://orcid.org/0000-0001-8012-8458)
- Nobuaki Kobayashi (ORCID: https://orcid.org/0000-0002-7064-320X)
- Toshiyuki Sumi (ORCID: https://orcid.org/0000-0002-2540-5878)
- Limin Sun (ORCID: https://orcid.org/0000-0002-2826-4812)
Institutions
- Sapporo Medical University (JP)
- Dalian Medical University (CN)
- Second Affiliated Hospital of Dalian Medical University (CN)
- Hakodate National Hospital (JP)
- Yokohama City University (JP)
Publication Details
- Journal
- Translational Cancer Research
- Published
- 2025-10-01
- DOI
- https://doi.org/10.21037/tcr-2025-2095
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.52